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1  | INTRODUC TION
Glaucoma is comprised of progressive optic neuropathies charac-
terized by degeneration of retinal ganglion cells (RGC) and resulting 
changes in the optic nerve. It is a complex disease where multiple 
genetic and environmental factors interact (Skowronska-Krawczyk 
et al., 2015; Weinreb, Aung, & Medeiros, 2014). Two of the leading 
risk factors, increased intraocular pressure (IOP) and age, are related 
to the extent and rate of RGC loss. Although lowering IOP is the 
only approved and effective treatment for slowing worsening of vi-
sion, many treated glaucoma patients continue to experience loss of 
vision and some eventually become blind. Several findings suggest 
that age-related physiological tissue changes contribute significantly 
to neurodegenerative defects that cause result in the loss of vision.
Mammalian aging is a complex process where distinct molecular 
processes contribute to age-related tissue dysfunction. It is notable 
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Abstract
Experimental ocular hypertension induces senescence of retinal ganglion cells (RGCs) 
that mimics events occurring in human glaucoma. Senescence-related chromatin re-
modeling leads to profound transcriptional changes including the upregulation of a 
subset of genes that encode multiple proteins collectively referred to as the senes-
cence-associated secretory phenotype (SASP). Emerging evidence suggests that the 
presence of these proinflammatory and matrix-degrading molecules has deleterious 
effects in a variety of tissues. In the current study, we demonstrated in a transgenic 
mouse model that early removal of senescent cells induced upon elevated intraocu-
lar pressure (IOP) protects unaffected RGCs from senescence and apoptosis. Visual 
evoked potential (VEP) analysis demonstrated that remaining RGCs are functional 
and that the treatment protected visual functions. Finally, removal of endogenous se-
nescent retinal cells after IOP elevation by a treatment with senolytic drug dasatinib 
prevented loss of retinal functions and cellular structure. Senolytic drugs may have 
the potential to mitigate the deleterious impact of elevated IOP on RGC survival in 
glaucoma and other optic neuropathies.
K E Y W O R D S
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that specific molecular processes underlying RGC damage in aging 
eyes are poorly understood. While no single defect defines aging, 
several lines of evidence suggest that activation of senescence is a 
vital	contributor	(He	&	Sharpless,	2017).
In a mouse model of glaucoma/ischemic stress, we reported the 
effects of p16Ink4a on RGC death (Skowronska-Krawczyk et al., 
2015). Upon increased IOP, the expression of p16Ink4a was elevated, 
and this led to enhanced senescence in RGCs and their death. Such 
changes most likely cause further RGC death and directly cause loss 
of vision. In addition, the analysis of p16KO mice suggested that lack 
of p16Ink4a gene protected RGCs from cell death caused by elevated 
IOP (Skowronska-Krawczyk et al., 2015). Importantly, elevated ex-
pression of p16INK4a and senescence were both detected in human 
glaucomatous eyes (Skowronska-Krawczyk et al., 2015). Therefore, 
for the first time, p16Ink4a was implicated as a downstream integra-
tor of diverse signals causing RGC aging and death, both character-
istics changes in the pathogenesis of glaucoma. Our findings were 
further	 supported	 by	 a	 subsequent	 report	 showing	 that	 p16Ink4a 
was	 upregulated	 by	 TANK	 binding	 kinase	 1	 (TBK1)	 a	 key	 regula-
tor of neuroinflammation, immunity, and autophagy activity. TBK 
also caused RGC death in ischemic retina injury (Li, Zhao, & Zhang, 
2017).	Of	particular	note,	a	recent	bioinformatic	meta-analysis	of	a	
published set of genes associated with primary open-angle glaucoma 
(POAG) pointed at senescence and inflammation as key factors in 
RGC	degeneration	in	glaucoma	(Danford	et	al.,	2017).
Glaucoma remains relatively asymptomatic until it is severe, and 
the number of affected individuals is much higher than the number 
diagnosed.	Numerous	clinical	studies	have	shown	that	lowering	IOP	
slows the disease progression (Boland et al., 2013; Sihota, Angmo, 
Ramaswamy,	&	Dada,	2018).	However,	RGC	and	optic	nerve	damage	
are not halted despite lowered IOP, and deterioration of vision pro-
gresses in most treated patients. This suggests the possibility that 
an independent damaging agent or process persists even after the 
original insult (elevated IOP) has been ameliorated.
We hypothesized that early removal of senescent RGCs that se-
crete senescent associated secretory proteins (SASP) could protect 
remaining RGCs from senescence and death induced by IOP ele-
vation. To test this hypothesis, we used an established transgenic 
p16-3MR mouse model (Demaria et al., 2014) in which the systemic 
administration of the small molecule ganciclovir (GCV) selectively 
kills p16INK4a-expressing cells. We show that the early removal of 
p16Ink4+ cells has a strong protective effect on RGC survival and 
visual function. We confirm the efficiency of the method by show-
ing the reduced level of p16INK4a expression and lower number 
F I G U R E  1   Removal of early senescent cells has a neuroprotective effect on RGCs. (a) Schematic representation of the p16-3MR 
transgene.	Triple	fusion	of	luciferase,	the	red	fluorescent	protein,	and	tyrosine	kinase	from	HSV	virus	are	under	control	of	the	regulatory	
region of p16Ink4a gene. (b) Plan of the experiment. After unilateral IOP elevation mice are daily injected with GCV (25 mg/kg) 
intraperitoneally. At day 5 VEP is measured, and tissue is collected for further experiments. (c) Representative images of retina flat-mount 
immunohistochemistry at day five with anti-Brn3a antibody specifically labeling ~80% of RGC cells. (d) Quantification of RGC number at 
day five after the treatment of WT animals. N	≥	5	animals	in	each	group	(e)	Quantification	of	RGC	number	at	day	five	after	the	treatment	of	
p163MR animals. N	=	8	animals	in	each	group.	In	d	and	e,	statistical	tests	were	performed	using	ANOVA	with	post	hoc	Tukey	correction	for	
multiple testing. *p < .05, **p < .01, ***p < .001, n.s., not significant
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of senescent β-galactosidase-positive cells after GCV treatment. 
Finally, we show that treatment of p16-3MR mice with a known se-
nolytic drug (dasatinib) has a similar protective effect on RGCs as 
compared to GCV treatment in p16-3MR mice.
2  | MATERIAL S AND METHODS
2.1 | Animals
All animal experiments were approved by the UC San Diego 
Institutional Animal Care and Use Committee (IACUC) and adhered 
to the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision	Research.	Adult	p16-3MR	(Demaria	et	al.,	2014)	or	C57BL/6	
mice (12–16 weeks old, Jackson Labs) were housed in 20°C environ-
ment with standard (12 hr light/dark) cycling, food, and water avail-
able	ad	 libitum.	For	all	experiments,	an	equal	number	of	male	and	
female mice were used.
2.2 | Drug treatment
The p16-3MR transgenic model (Figure 1a), in which the mice carry a 
trimodal reporter protein (3MR) under the control of p16 regulatory 
region (Demaria et al., 2014), allows potent selective removal of se-
nescent cells. The 3MR transgene encodes a fusion protein consist-
ing of Renilla luciferase, a monomeric red fluorescent protein (mRFP) 
and	herpes	simplex	virus	thymidine	kinase	(HSV-TK)	which	converts	
ganciclovir	 (GCV)	 into	a	 toxic	DNA	chain	 terminator	 to	selectively	
kill	HSV-TK	expressing	cells.	The	experimental	group	of	animals	was	
treated by intraperitoneal (IP) administration of GCV (Sigma, 25 mg/
kg once a day) or dasatinib (Sigma, 5 mg/kg) after IOP elevation (see 
below), and a control group of mice was sham-treated with PBS or 
vehicle (DMSO). Each mouse underwent unilateral hydrostatic pres-
sure-induced	IOP	elevation	to	90	mm	Hg,	with	the	contralateral	eye	
left as an untreated control. The mice were IP injected intraperito-
neally with GCV or dasatinib at day 0 (IOP elevation day) and con-
tinued for four consecutive days (Figure 1b). At day 5, animals were 
euthanized, and retinas were isolated and immunostained with anti-
Brn3a antibody to evaluate the number of RGCs. All drugs were pre-
pared according to the UC San Diego Institutional Animal Care and 
Use Committee (IACUC) standards. To ensure a sterile environment, 
compounds were prepared under the tissue culture hood using ster-
ile PBS. The final solution was filtered through a 0.22-µm PES mem-
brane just before injection. Tips, tubes, and syringes were sterile.
2.3 | Hydrostatic intraocular pressure 
(IOP) elevation
Animals were anesthetized with an intraperitoneal injection of keta-
mine/xylazine cocktail, (100 and 10 mg/kg, respectively), their eyes 
anesthetized with one drop of proparacaine (0.5%, Bausch-Lomb) 
and dilated with one drop of tropicamide (1%, Alcon Laboratories). 
Unilateral elevation of IOP was achieved by infusing balanced salt 
solution (Alcon Laboratories) into the anterior chamber of the eye 
through using an intravenous (IV) infusion set. The level of IOP in-
crease was determined by the height of the saline bottles on the 
IV	 infusion	 set.	 Stable	 elevated	 IOP	 of	 85–90	mm	Hg	 was	 main-
tained for 60 min and controlled by IOP measurements using a vet-
erinary rebound tonometer (Tonovet). Both eyes were lubricated 
throughout testing with an ophthalmic lubricant gel (GenTeal, Alcon 
Laboratories). Animals recovered on a Deltaphase isothermal pad 
(Braintree Scientific) until awake. The contralateral eye without IOP 
elevation served as a healthy non-IOP control (CTRL).
2.4 | Visual evoked potential
VEP measurements were taken at five days post-IOP elevation. 
This	protocol	was	adapted	from	prior	studies	(Ridder	&	Nusinowitz,	
2006). Mice were dark-adapted for at least 12 hr before the proce-
dure. Animals were anesthetized with ketamine/xylazine and their 
eyes dilated as above. The top of the mouse's head was cleaned with 
an antiseptic solution. A scalpel was used to incise the scalp skin, 
and a metal electrode was inserted into the primary visual cortex 
through the skull, 0.8 mm deep from the cranial surface, 2.3 mm lat-
eral to the lambda. A platinum subdermal needle (Grass Telefactor) 
was inserted through the animal's mouth as a reference and through 
the tail as ground. The measurements commenced when the base-
line waveform became stable, 10–15 s after attaching the electrodes. 
Flashes of light at 2 log cd.s/m2 were delivered through a full-field 
Ganzfeld	bowl	at	2	Hz.	Signal	was	amplified,	digitally	processed	by	
the software (Veris Instruments), then exported, and peak-to-peak 
responses were analyzed in Excel (Microsoft). To isolate VEP of the 
measured eye from the crossed signal originating in the contralat-
eral eye, a black aluminum foil eyepatch was placed over the eye not 
undergoing measurement. For each eye, peak-to-peak response am-
plitude	of	the	major	component	P1-N1	in	IOP	eyes	was	compared	to	
that of their contralateral non-IOP controls. Following the readings, 
the animals were euthanized, and their eyes collected and processed 
for immunohistological analysis.
2.5 | Immunohistochemistry
Following euthanasia, eyes were enucleated and fixed in 4% para-
formaldehyde	 (PFA)	 in	PBS	 (Affymetrix)	 for	1	hr	and	subsequently	
transferred to PBS. The eyes were then dissected, the retinas flat-
mounted on microscope slides, and immunostained using a standard 
sandwich assay with anti-Brn3a antibodies (Millipore, MAB1595) 
and	 secondary	 AlexaFluor	 555	 anti-mouse	 (Invitrogen,	 A32727).	
Mounted samples (Fluoromount, Southern Biotech 0100-01) were 
imaged in the fluorescent microscope at 20x magnification (Biorevo 
BZ-X700,	 Keyence),	 focusing	 on	 the	 central	 retina	 surrounding	
the optic nerve. Overall damage and retina morphology were also 
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taken into consideration for optimal assessment of the retina integ-
rity.	Micrographs	were	quantified	using	manufacturer	software	for	
Brn3a-positive cells in 6 independent 350 × 350 µm areas per flat 
mount.
2.6 | Real-time PCR
Total	 RNA	 extraction	 from	 mouse	 tissues,	 cDNA	 synthesis,	 and	
RT-qPCR	 experiments	 were	 performed	 as	 previously	 described	
(Skowronska-Krawczyk et al., 2015). Assays were performed in trip-
licate.	Relative	mRNA	levels	were	calculated	by	normalizing	results	
using	GAPDH.	 The	 primers	 used	 for	 RT-qPCR	 are	 the	 same	 as	 in	
(Skowronska-Krawczyk	et	al.,	2015).	The	differences	in	quantitative	
PCR data were analyzed with an independent two-sample t test.
2.7 | SA-βgal assay to test senescence on retinas 
mouse eyes
Senescence assays were performed using the Senescence b-Galac-
tosidase Staining Kit (Cell Signaling) according to the manufacturer's 
protocol.	 Images	 were	 acquired	 using	 a	 Hamamatsu	 Nanozoomer	
2.0HT	 Slide	 Scanner	 and	 quantified	 in	 independent	 images	 of	
0.1 mm2 covering the areas of interest using Keyence software.
2.8 | RNA-Seq analysis
High-quality	RNA	was	extracted	using	TRIzol	Reagent	 (Invitrogen)	
and	treated	with	TURBO	DNA-free	Kit	(Invitrogen).	RNA-Seq	librar-
ies	were	made	from	1	µg	total	RNA	per	tissue	sample	using	TruSeq	
stranded	mRNA	Library	Prep	Kit	(Illumina,	kit	cat.	no.	20020597)	ac-
cording to the manufacturer's instructions. The libraries were size-
selected using Agencourt Ampure XP beads (Beckman Coulter) and 
quality-checked	by	Bioanalyzer	(Agilent).	The	strand-specific	RNA-
Seq	paired-end	reads	sequence	data	(PE50:	2	×	50	bp)	were	obtained	
on	a	HiSeq4000.	RNA-Seq	reads	were	counted	using	HOMER	soft-
ware	considering	only	exonic	regions	for	RefSeq	genes.
3  | RESULTS
Intraocular pressure was increased in one eye of transgenic mice 
bearing the p16-3MR construct (Figure 1a). After IOP elevation, 
mice were intraperitoneally injected with GCV for five consecutive 
days (Figure 1b) to specifically deplete p16Ink4a-positive (p16+) cells. 
In parallel, wild-type animals were subjected to the same protocol, 
that is, underwent five daily GCV injections after unilateral IOP el-
evation.	Retina	flat-mount	immunohistochemistry	and	RGC	quanti-
fication were used to assess potential impact of drug treatment. We 
observed that five-day administration of GCV after IOP elevation 
F I G U R E  2   Visual functions are 
preserved in animals when senescent 
cells were removed. (a) Schematic 
representation of the placement of 
electrodes for VEP measurements. (b) 
Example results of VEP experiments. Top: 
results of the VEP response of healthy 
and IOP-treated eyes. Bottom: After GCV 
injections, the VEP response is protected. 
(c) Quantification of VEP responses at day 
five after the treatment of WT animals. 
N ≥	4,	(d)	Quantification	of	VEP	responses	
at day 5 after the treatment of the p16-
3MR animals. N ≥	6.	In	c	and	d,	statistical	
tests	were	performed	using	ANOVA	with	
post hoc Tukey correction for multiple 
testing. *p < .05, **p < .01, ***p < .001, 
n.s., not significant
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had a significant protective effect on Brn3a+ RGC number in p16-
3MR mice when compared to untreated eye (Figure 1c,1). This pro-
tection was not observed in WT animals (Figure 1e) confirming that 
the effect of the GCV injection is specific to the mice harboring the 
GCV-sensitive transgene.
Next,	to	test	whether	the	protection	of	RGC	numbers	 in	GCV-
treated retinas was accompanied by the protection of the visual cir-
cuit integrity on day five, the in vivo signal transmission from the 
retina to the primary visual cortex was assessed by measuring visual 
evoked potentials (VEP) (Figure 2a)(Bui & Fortune, 2004; Porciatti, 
2015). In brief, the reading electrode was placed in the striate vi-
sual cortex, with the reference electrode in the animal's mouth 
and ground electrode in the tail. Flash stimuli were presented in a 
Ganzfeld	bowl.	Response	amplitudes	were	quantified	from	the	peak-
to-peak	analysis	of	the	first	negative	component	N1.	Using	this	ap-
proach, we have found that eyes subjected to IOP elevation showed 
decreased	VEP	P1-N1	 amplitude	 (Figure	2b),	 compared	 to	 contra-
lateral	non-IOP	control	eyes.	However,	there	was	a	marked	rescue	
of VEP signals in transgenic animals treated with GCV (Figure 2b). 
Further	quantification	 showed	significant	vision	 rescue	upon	GCV	
treatment only in p16-3MR and not WT animals (Figure 2c,2), con-
firming the specificity of GCV treatment.
Our previous studies indicated that the increase in p16INK4a 
expression could be first observed as early as day three post-IOP 
elevation (Skowronska-Krawczyk et al., 2015). Therefore, we chose 
this time-point to analyze the effectiveness of GCV treatment on se-
nescent cells in treated and control retinas of p16-3MR animals. RGC 
quantification	 showed	 that	 in	 animals	 not	 injected	with	GCV	only	
~15%–20% of cells disappeared at day 3 (compared to ~45%–50% 
on day 5).
To test whether GCV treatment indeed removed senescent 
cells	in	the	retina,	we	used	two	approaches.	First,	we	quantified	the	
p16Ink4a expression at day three post IOP treatment in GCV-treated 
and control retinas. Expectedly, GCV treatment prevented IOP-
induced increase in p16Ink4a expression observed in non treated 
eyes (Figure 3b). Importantly, this was accompanied by significant 
decrease in numbers of IOP-induced β-galactosidase-positive senes-
cent cells in 3-day GCV treated retinas as compared to nontreated 
cells (Figure 3c,3). This indicates that IOP-induced early senescent 
cells are efficiently removed by GCV treatment by day 3, what pre-
cedes the RGC loss observed in non-treated eyes between day 3 
and day 5.
We next set forward on trying to understand molecular changes 
underlying the apparent protective effect of the removal of senes-
cent cells by GCV treatment in p16-3MR animals.
First, we performed time-course experiment in wild-type mice 
to follow the activation of caspase expression as a marker of endog-
enous	stress	 in	the	cell	 (Figure	4a).	We	quantified	both	total	num-
ber of RGC (by nuclear staining for RGC specific transcription factor 
Brn3a) and activated caspase-positive cells (by phospho-caspase 
3 staining). The highest number of RGCs with concomitant stain-
ing of activated caspase was observed at day 3 after IOP eleva-
tion (Figure 4a right). As shown above, at day 3 most of the RGCs 
are still present (Figure 3a). Day 3 also corresponds to the highest 
F I G U R E  3   Senescence is lowered 
upon GCV treatment ~2 days before the 
effects on RGC numbers are observed. 
(a) At day 3 after IOP, only 20% of RGCs 
are lost compared to the non-treated 
eye. Similar numbers of cells are lost in 
GCV-treated eyes at this stage. N = 3 
(non-GCV) and N	=	5	(GCV),	ANOVA,	
*p < .05, **p < .01, n.s. – not significant (b) 
p16Ink4a expression is significantly lower 
in affected retinas isolated from GCV-
treated p16-3MR animals at day 3 after 
IOP elevation. t-test, **p	<	.01	(c)	Number	
of SA-b-gal positive cells is lowered upon 
GCV treatment. Blue arrow – remaining 
senescent cell (d). Quantification of 
number of senescent cells upon IOP 
elevation in retinas isolated from mouse 
treated and non-treated with GCV. 
N = 4 (non-GCV), N	=	6	(GCV);	ANOVA,	
**p < .01
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expression levels of senescence-associated factors, as previously 
observed (Skowronska-Krawczyk et al., 2015). We thus reasoned 
that relevant effects of GCV treatment should be easy to observe 
at around this stage. To identify potential differences in an unbiased 
way,	we	 performed	RNA-seq	 analysis	 in	 IOP	 and	 non-IOP	 retinas	
with	or	without	GCV	treatment.	Total	RNA	isolated	from	3	retinas	
in	 each	 experimental	 group	was	 converted	 to	 cDNA	 libraries	 and	
sequenced.	Of	the	total	21,351	detected	gene	loci,	1601	were	sig-
nificantly de-regulated by the IOP treatment; 999 detected gene 
loci were up regulated; and 602 down-regulated (Figure 4b, top). 
When the IOP treatment was performed in mice treated with GCV, 
the	total	numbers	of	IOP-affected	genes	changed	modestly	to	1707,	
with 848 up regulated and 859 down-regulated (Figure 4b, bottom).
To	 inquire	 in	 an	unbiased	way	 about	 the	differences	 in	 signal-
ing pathways and cellular processes affected by IOP, GO analysis 
using	 PANTHER	was	 performed	 (Mi,	Muruganujan,	 Ebert,	 Huang,	
& Thomas, 2019). This approach revealed that processes of the 
immune system response, inflammation, and extracellular matrix 
composition and cell–matrix interaction were significantly changed 
in IOP samples (Table 1). We have also detected the significantly 
deregulated genes involved in apoptosis, microglial activation and 
interlukin-6 and interlukin-8 production and secretion. This analysis 
shows that many mechanisms are induced upon an acute IOP eleva-
tion, most probably causing additional transcriptional stress to cell.
Further analysis revealed that the genes involved in cellular se-
nescence, extracellular matrix molecules and in factors involved in 
apoptosis (Table 2) (Pawlikowski et al., 2013) were significantly de 
regulated upon IOP elevation. Importantly, 3-day treatment to re-
move p16 + cells significantly mitigated this response (Figure 4c). 
These data are in agreement with the loss of the senescence cells 
upon GCV treatment (Figure 3b3) and lower detrimental impact of 
senescent cells on surrounding cells.
Additional	GO	analysis	of	the	617	genes	which	were	significantly	
de regulated upon IOP elevation specifically in non treated reti-
nas (i.e., genes where the effects of IOP were dampened by GCV-
mediated removal of senescent cells) (Figure 4d) identified a specific 
enrichment of a class of genes belonging to the ABL1 pathway and 
ABL1 downstream targets (Fig. S1). Prompted by this finding, we 
F I G U R E  4   Analysis of pathways 
affected in IOP-treated retinas. (a) 
Immunohistochemistry of Brn3a and 
activated caspase show increase of 
apoptosis at days1, 2 and 3 after IOP 
treatment.	left:	quantification	of	the	
time-course experiments followed 
by immunochemistry with Brn3a and 
activated	caspase	3;	(b)	RNA-seq	
analysis of response to IOP and GCV. 
Eyes subjected to IOP elevation show 
significant change in gene expression 
with more genes upregulated than 
downregulated. Similar analysis in 
GCV-treated animals shows close to 
equal	distribution	of	upregulated	and	
downregulated	genes	c.	Heatmap	analysis	
of genes involved in senescence, active 
oxidative species (ROS), apoptosis, 
extracellular matrix homeostasis (ECM), 
and inflammation. (d) Venn diagram 
showing overlap between genes 
dysregulated upon IOP in GCV-treated 
and	GCV-untreated	retinas.	A	total	of	617	
genes specifically dysregulated in IOP 
only retinas were used for GO analysis
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explored whether dasatinib, a well-known senolytic drug and a Bcr-
Abl and Src family threonine kinase inhibitor, could have a beneficial 
effect similar to GCV in p16-3MR mice. To this end, p16-3MR mice 
were treated with dasatinib (5 mg/kg) or vehicle for 5 days by intra-
peritoneal injection, similarly to the experimental procedure used for 
GCV (Figure 1b). Performing this experiment in the transgenic mice 
allowed direct comparison of the efficiencies of both treatments in 
the same mouse strain. At day five after IOP elevation, VEP mea-
surement	was	performed	and	retinas	were	immunostained	to	quan-
tify RGC loss. We observed that dasatinib treatment prevented the 
loss of RGC (Figure 5c) similar to what was observed in GCV-treated 
animals (Figure 1e). Most importantly, VEP analysis revealed that se-
nolytic drug treatment successfully prevented vision loss upon IOP 
elevation (Figure 5d).
Finally, we explored whether the protective impact of the drug 
is caused by the sustained inhibition of the cellular processes and 
whether it is maintained even after the drug is no longer present. 
To do that, p16-3MR mice were treated with dasatinib (5 mg/kg) or 
vehicle for 5 days by intraperitoneal injection, similarly to the ex-
perimental procedure used for GCV (Figure 1b). After that, the mice 
were no longer treated with drug or PBS and at day twelve after IOP 
elevation, functional measurement was performed and RGCs were 
quantified.	 Also	 in	 this	 treatment	 regime,	 dasatinib	 prevented	 the	
loss of RGC (Figure 5c) similar to what was observed in GCV-treated 
animals (Figure 1e). Additionally, VEP analysis revealed that senolytic 
drug treatment with seven days “chase” still successfully prevented 
vision loss upon IOP elevation (Figure 5d).
4  | DISCUSSION
The collective findings of the current study strongly support the no-
tion that removal of senescent cells provides beneficial protective 
effect	 to	 retinas	damaged	by	elevated	 IOP.	Here,	we	show	that	 in	
transgenic animals expressing viral TK under the control of regula-
tory regions of p16Ink4a (Demaria et al., 2014), selective removal of 
early senescent cells in the retina is beneficial for neighboring cells 
undergoing cellular stress induced by IOP elevation. In this model, 
the treatment with GCV selectively induces cell death of transgene-
expressing cells. Early application of GCV as soon as day 0 after the 
IOP elevation and followed for five consecutive days ensures early 
removal of p16Ink4a expressing cells resulting in protection of neigh-
boring RGCs from death. Remaining cells are still able to provide a 
signal to the visual cortex, as evidenced by VEP measurements, dem-
onstrating that protected cells are functional.
Three days after GCV injection, there is a significant drop in 
senescent cell number and an accompanying alteration of the tran-
scriptional programs in remaining cells as compared to retinas from 
untreated	mice.	Using	an	RNA-seq	approach,	we	noted	significant	
changes in the senescence program as well as in the extracellular 
matrix (ECM) function. Both pathways are downregulated by GCV 
treatment. Finally, we show that dasatinib, a known senolytic drug, 
can be used to protect RGCs from death, further confirming that 
early removal of senescent cells induced upon IOP elevation pro-
tects retina health. The observation also was confirmed when the 
RGC count and VEP were assessed seven days after the treatment 
was stopped; this suggests that the impact of the drug is not re-
versible during this time. Further studies should investigate different 
regimes and dosages of the senolytic drugs and their neuroprotec-
tive role in particular to investigate the efficiency in the removal of 
senescent cells from the tissue.
Taken together, the results prompt us to propose a model of how 
increased IOP leads to the destruction of retinal structures during 
glaucoma progression (Figure 5e). During early stages, elevated IOP 
induces cell-intrinsic changes leading to cellular senescence and pro-
duction of SASP. As the disease worsens, SASP molecules induce 
apoptosis and senescence in neighboring cells. Such changes are 
largely independent of whether the initial insult is still present or 
has been eliminated with IOP-lowering treatment. RGC apoptosis 
inevitably leads to the loss of axons and optic nerve degeneration. 
Conversely, when senescent cells (induced directly by elevated IOP) 
are removed using senolytic drugs (Figure 5e, bottom), neighboring 
cells are not exposed to detrimental SASP and remain healthy. We 
propose that such treatment can lead reduce the rate of glaucoma 
worsening. Moreover, we speculate that changes in combination 
with IOP-lowering treatments may have even better protection than 
either type of therapy alone.
We	 and	 others	 previously	 used	 90	 mm	 Hg	 as	 an	 extremely	
acute and reproducible way to induce cell response and RGC death 
(Skowronska-Krawczyk et al., 2015). This level of pressure is likely 
an	ischemic	insult.	The	resulting	synchronized	and	quick	cell	death	
provide	 unique	 qualities	 that	 are	 extremely	 useful	 for	 molecular	
and biochemical studies; however such an acute and high-pressure 
change is not fully representative of POAG, a chronic optic neurop-
athy.	However,	this	acute	insult	allows	the	study	of	stress	response	
time course and can help unravel important aspects of stepwise re-
sponse of retinal cells to elevated IOP which is a daunting task to 
assess in chronic models the disease. Importantly, our previous data 
showing the presence of senescent cells in human glaucomatous ret-
inas (Skowronska-Krawczyk et al., 2015) should stimulate the use of 
senolytic drugs in other animal models of glaucoma.
Dasatinib is a selective tyrosine kinase receptor inhibitor that 
is commonly used in the therapy of chronic myelogenous leukemia 
(CML). Other studies have shown that treatment with dasatinib is ef-
fective in destroying senescent fat cell precursors (Zhu et al., 2015). 
Our	RNA-seq	data	pointed	to	this	senolytic	drug	as	a	potential	can-
didate for in vivo treatment of retinal damage induced by IOP eleva-
tion.	Notably,	we	found	that	the	level	of	RGC	protection	resembles	
the one obtained with GCV treatment of p16-3MR transgenic line. 
Based on these findings, we conclude that dasatinib treatment re-
sulted in RGC protection through removal of senescent cells. It will 
be of interest to further investigate the possible therapeutic effects 
of other senolytic drugs in glaucoma and glaucoma models.
The gene encoding p16INK4a, CDKN2A,	 lies	 within	 the	 INK4/
ARF tumor suppressor locus on human chromosome 9p21; this is 
the most significant region to be identified as having an association 
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with	POAG	in	different	population	samples	(Ng,	Casson,	Burdon,	&	
Craig, 2014). Although the molecular mechanism of many of these 
associations is yet to be described, we have shown that one of them 
especially highly correlates with the presence of another top risk 
variant of glaucoma—Six6 rs33912345. Our study further showed 
that upregulation of homozygous SIX6 risk alleles (CC) leads to an 
increase in p16Inka	expression,	with	subsequent	cellular	senescence	
(Skowronska-Krawczyk et al., 2015). Interestingly, others have de-
scribed an alternative mechanism whereby IOP-induced TBK1 ex-
pression caused an increase of p16Ink4a expression through the 
TA B L E  2   List of genes in pathways represented in Figure 4c
Apoptosis ECM SASP
Abl1 Adamts1 Ang5
Actb Adamts2 Areg
Aifm1 Adamts5 Ccl11
Akt1 Adamts8 Ccl12
Anxa5 Cdh1 Ccl2
Apaf1 Cdh2 Ccl20
Api5 Cdh3 Ccl7
Atf5 Cdh4 Csf2
Bag1 Cntn1 Csf3
Bag3 Col1a1 Ctsb
Bak1 Col2a1 Cxcl11
Bax Col3a1 Cxcl12
Bcl10 Col4a1 Cxcl13
Bcl2a1a Col4a2 Egf
Bcl2l10 Col4a3 Egfr
Bcl2l2 Col5a1 Ereg
Bid Col6a1 Fas
Birc2 Ctgf Fgf2
Birc3 Ctnna1 Fgf7
Birc5 Ctnna2 Fn1
Bnip2 Ctnnb1 Hgf
Bok Ecm1 Icam1
Card10 Emilin1 Ifng
Casp1 Entpd1 Igfbp2
Casp12 Fbln1 Igfbp3
Casp14 Fn1 Igfbp4
Casp2 Hapln1 Igfbp5
Casp3 Hc Igfbp6
Casp4 Icam1 Igfbp7
Casp6 Itga2 Il13
Casp7 Itga3 Il15
Casp8 Itga4 Il1a
Casp9 Itga5 Il1b
Cd40lg Itgae Il6
Cd70 Itgal Il6st
Cflar Itgam Il7
Cidea Itgav Mip
Cideb Itgb1 Mmp12
Cradd Itgb2 Mmp13
Dad1 Itgb3 Mmp14
Dapk1 Itgb4 Mmp1a
Dffa Lama1 Mmp2
Dffb Lama2 Mmp3
Diablo Lama3 Mmp7
Fas Lamb2 Mmp9
(Continues)
Apoptosis ECM SASP
Fasl Lamb3 Ngf
Gadd45a Lamc1 Pigf
Gapdh Mmp10 Plaur
Gusb Mmp11 Serpinb2
Hsp90ab1 Mmp13 Serpine1
Igf1r Mmp14 Timp1
Il10 Mmp15 Timp2
Lhx4 Mmp1a Tnfrsf11b
Ltbr Mmp2 Tnfrsf1a
Mapk1 Mmp3 Tnfrsf1b
Mcl1 Mmp7 Tnfrsf22
Naip1 Mmp8  
Naip2 Mmp9  
Nfkb1 Ncam1  
Nme5 Ncam2  
Nod1 Pecam1  
Nol3 Postn  
Polb Sele  
Prdx2 Sell  
Ripk1 Selp  
Tnfrsf10b Sgce  
Tnfrsf11b Sparc  
Tnfrsf1a Spock1  
Tnfsf10 Spp1  
Tnfsf12 Syt1  
Traf1 Tgfbi  
Traf2 Thbs1  
Trp53 Thbs2  
Trp53bp2 Thbs3  
Trp63 Timp1  
Trp73 Timp2  
Xiap Timp3  
 Tnc  
 Vcam1  
 Vcan  
 Vtn  
TA B L E  2   (Continued)
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Akt-	Bmi1	phosphorylation	pathway	(Li	et	al.,	2017).	Given	the	com-
plexity of the 9p21 locus, we believe that there are more pathways 
involved in p16Ink4a regulation and further work is needed to under-
stand the role of p16Ink4a as a integrator of these signals especially 
upon IOP elevation.
Several	 collaborative	 efforts	 identified	 numerous	 SNPs	 local-
ized within the 9p21 locus to be highly associated with the risk of 
open-angle	 glaucoma	 including	 normal-tension	 glaucoma	 (NTG),	 a	
glaucomatous optic neuropathy not associated with elevated IOP 
(Killer	&	Pircher,	2018;	Wiggs	&	Pasquale,	2017).	 Intriguingly,	 one	
of	the	top	variants	associated	with	the	risk	of	NTG	is	located	in	the	
gene TBK1, a factor that has been recently shown to be implicated 
in upregulation of p16ink4a	 gene	 (Li	 et	 al.,	 2017).	 Finally,	 recent	
studies have also revealed that specific methylation patterns in the 
9p21	 locus	are	strongly	associated	with	 the	 risk	of	NTG	glaucoma	
(Burdon, 2018). It is notable that the positions of most, if not all, of 
these	SNPs	and	methylation	markers	overlap	with	active	regulatory	
regions	within	the	locus	identified	by	ENCODE	(Consortium,	2012).	
Although regulation of the 9p21 locus in the context of many dis-
eases and aging is under extensive investigation, it still remains to be 
explicitly addressed in relation to glaucoma.
Another major type of glaucomatous optic neuropathy is angle 
closure glaucoma (ACG), a condition characterized by blockage of 
the drainage angle of the eye. To date, there is no study reporting 
F I G U R E  5   Dasatinib protects retina degeneration. (a) Plan of the experiment. After unilateral IOP elevation, mice are daily injected with 
dasatinib (5 mg/kg) intraperitoneally. At day 5, VEP is measured and tissue is collected for further experiments. Immunohistochemistry of 
Brn3a and activated caspase show increase of apoptosis at day 3 after IOP treatment. (b) Retina flat-mount immunohistochemistry at day 
5 with anti-Brn3a antibody specifically labeling ~80% of RGC cells. (c,d) Quantification of RGC number (c) or VEP responses (d) at day 5 
(four	conditions)	or	day	12	(additional	7	days	of	“recovery,”	two	conditions)	after	the	5	days	treatment	of	p16-3MR	animals	with	dasatinib.	
N	>	4	animals	in	each	group.	Statistical	tests	were	performed	using	ANOVA	with	post	hoc	Tukey	correction	for	multiple	testing.	*p < .05, 
***p < .001, n.s. – not significant (e). Model. Top: Upon elevated IOP damaged cells become senescent and start to express SASP molecules. 
While disease progresses, the SASP molecule induces senescence or apoptosis in neighboring cells. Bottom: When senescent cells are 
removed using senolytic drug the neighboring cells are not exposed to detrimental SASPs and the disease progression is significantly slowed 
down. Remaining cells are healthy
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genetic variants or methylation markers in the 9p21 locus signifi-
cantly associated with the risk of ACG despite several studies im-
plicating various molecular mechanisms (Evangelho, Mogilevskaya, 
Losada-Barragan,	&	Vargas-Sanchez,	2019).	Nevertheless,	 the	 fact	
that progressive vision loss is observed in PACG patients, even after 
lowering	the	IOP	(Brubaker,	1996),	raises	the	question	whether	an	
association could be observed between 9p21 markers and the pro-
gression rather than the risk of the disease. Further studies to unravel 
such associations are necessary.
Markers of cellular senescence such as expression of the p16Ink4a 
and SASP molecules dramatically increase during aging in both hu-
mans and mice. Several studies suggest that p16Ink4a + cells act to 
shorten healthy lifespan by promoting age-dependent changes that 
functionally impair tissues and organs (Baker et al., 2016; Childs et 
al.,	2016;	Jeon	et	al.,	2017;	Krishnamurthy	et	al.,	2006).	Intriguingly,	
a recent explosion of studies has shown that removal of senescent 
cells using senolytic drugs in progeroid (accelerated aging pheno-
type) and healthy mice induces lifespan extension and improves the 
health	of	animals	(Baker	et	al.,	2011,	2016;	Scudellari,	2017;	Xu	et	al.,	
2018). Our studies suggest a potential use of such therapy to reduce 
glaucoma associated blindness, either as a stand-alone treatment or 
together with IOP-lowering therapies.
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